X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4675) 4675
Newsletter (29) 29
Book Chapter (13) 13
Dissertation (7) 7
Newspaper Article (6) 6
Magazine Article (2) 2
Reference (2) 2
Conference Proceeding (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
fludarabine (3951) 3951
humans (3345) 3345
hematology (2388) 2388
oncology (2080) 2080
male (2014) 2014
female (1923) 1923
middle aged (1736) 1736
aged (1479) 1479
adult (1372) 1372
vidarabine - analogs & derivatives (1303) 1303
cyclophosphamide (1152) 1152
rituximab (1146) 1146
leukemia, lymphocytic, chronic, b-cell - drug therapy (1024) 1024
treatment outcome (905) 905
therapy (881) 881
chronic lymphocytic leukemia (879) 879
transplantation (852) 852
antineoplastic combined chemotherapy protocols - therapeutic use (799) 799
chronic lymphocytic-leukemia (679) 679
chemotherapy (678) 678
cancer (672) 672
leukemia (662) 662
vidarabine - administration & dosage (614) 614
antineoplastic agents - therapeutic use (606) 606
aged, 80 and over (543) 543
immunology (527) 527
cll (525) 525
care and treatment (511) 511
prognosis (505) 505
survival (504) 504
vidarabine - therapeutic use (488) 488
bone-marrow-transplantation (460) 460
stem-cell transplantation (451) 451
adolescent (444) 444
leukemia, lymphocytic, chronic, b-cell - pathology (419) 419
stem cells (417) 417
disease-free survival (412) 412
retrospective studies (396) 396
transplantation conditioning - methods (393) 393
alemtuzumab (381) 381
hematopoietic stem cells (377) 377
lymphoma (368) 368
research (367) 367
transplantation, homologous (359) 359
health aspects (348) 348
apoptosis (334) 334
cyclophosphamide - administration & dosage (332) 332
survival analysis (328) 328
hematopoietic stem cell transplantation (327) 327
antineoplastic combined chemotherapy protocols - adverse effects (322) 322
survival rate (322) 322
remission induction (318) 318
hematology, oncology and palliative medicine (317) 317
risk factors (317) 317
leukemia, lymphocytic, chronic, b-cell - mortality (314) 314
recurrence (311) 311
chlorambucil (310) 310
stem cell transplantation (310) 310
vidarabine - adverse effects (301) 301
leukemia, lymphocytic, chronic, b-cell - therapy (293) 293
trial (293) 293
child (287) 287
young adult (276) 276
follow-up studies (273) 273
hematopoietic stem cell transplantation - methods (272) 272
analysis (271) 271
fludarabine plus cyclophosphamide (271) 271
antineoplastic agents - adverse effects (270) 270
antibodies, monoclonal - therapeutic use (269) 269
leukemia, lymphocytic, chronic, b-cell - genetics (269) 269
busulfan (267) 267
antineoplastic agents (262) 262
versus-host-disease (259) 259
pharmacology & pharmacy (257) 257
diagnosis (256) 256
medicine & public health (248) 248
drug therapy (247) 247
patients (246) 246
acute myeloid-leukemia (242) 242
toxicity (242) 242
combination (240) 240
expression (239) 239
cladribine (233) 233
antineoplastic combined chemotherapy protocols - administration & dosage (232) 232
antimitotic agents (231) 231
dosage and administration (231) 231
non-hodgkins-lymphoma (230) 230
animals (223) 223
chemoimmunotherapy (223) 223
bone marrow (219) 219
immunotherapy (218) 218
phase-ii trial (218) 218
open-label (217) 217
regimen (217) 217
cytarabine (209) 209
hemic and lymphatic diseases (209) 209
initial therapy (209) 209
child, preschool (208) 208
vidarabine - pharmacology (208) 208
children (202) 202
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4573) 4573
German (37) 37
French (35) 35
Russian (20) 20
Polish (18) 18
Spanish (13) 13
Chinese (8) 8
Japanese (8) 8
Czech (7) 7
Hungarian (6) 6
Korean (4) 4
Portuguese (4) 4
Slovak (3) 3
Turkish (3) 3
Romanian (2) 2
Slovenian (2) 2
Dutch (1) 1
Persian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of hematology and oncology, ISSN 1756-8722, 2019, Volume 12, Issue 1, pp. 44 - 10
BackgroundLimited data is available to guide the choice of the conditioning regimen for patients with acute myeloid leukemia (AML) undergoing transplant with... 
Conditioning regimen | Fludarabine, intermediate dose Ara-C, amsacrine, total body irradiation/busulfan, cyclophosphamide (FLAMSA) | Thiotepa-busulfan-fludarabine (TBF) | Active disease | Allogeneic transplantation | Sibling donor (MSD) | Fludarabine-treosulfan (FT) | Unrelated donor (UD) | Acute myeloid leukemia (AML) | SURVIVAL | AML | UNRELATED DONORS | intermediate dose Ara-C | CHEMOTHERAPY | busulfan | GLOBULIN | Fludarabine | ONCOLOGY | REDUCED-TOXICITY | HOST-DISEASE PROPHYLAXIS | total body irradiation | STEM-CELL TRANSPLANTATION | HEMATOLOGY | amsacrine | cyclophosphamide (FLAMSA) | Thiotepa - therapeutic use | Busulfan - analogs & derivatives | Busulfan - pharmacology | Busulfan - therapeutic use | Leukemia, Myeloid, Acute - pathology | Europe | Humans | Middle Aged | Male | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Young Adult | Vidarabine - pharmacology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aged | Retrospective Studies | Thiotepa - pharmacology | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning - methods | Cyclophosphamide | Relapse | Care and treatment | Oncology, Experimental | Mortality | Bone marrow | Transplantation | Research | Health aspects | Cancer | Diseases | Graft-versus-host reaction | Transplants & implants | Myeloid leukemia | Leukemia | Radiation | Serology | Treosulfan | Survival | Studies | Chemotherapy | Thymocytes | Globulins | Stem cells | Remission | Busulfan | Acute myeloid leukemia
Journal Article
Blood, ISSN 1528-0020, 2018, Volume 131, Issue 17, pp. 1910 - 1919
Our 5-year experience shows sustained single-agent efficacy of ibrutinib in CLL patients, with complete response rates increasing over time. Long-term... 
BENDAMUSTINE | MULTICENTER | FLUDARABINE PLUS CYCLOPHOSPHAMIDE | CHEMOIMMUNOTHERAPY | RITUXIMAB | INITIAL THERAPY | OPEN-LABEL | CLL8 TRIAL | HEMATOLOGY | CHLORAMBUCIL | PREVIOUSLY UNTREATED PATIENTS | Clinical Trials and Observations
Journal Article
Blood, ISSN 1528-0020, 2018, Volume 132, Issue 15, pp. 1568 - 1572
Cytoreduction with obinutuzumab and ibrutinib followed by the addition of venetoclax has acceptable safety with no tumor lysis syndrome. This combination has... 
ANTIBODIES | OPEN-LABEL | THERAPY | HEMATOLOGY | FLUDARABINE | RITUXIMAB | 8 | 12 | Clinical Trials and Observations | 39
Journal Article
Haematologica (Roma), ISSN 1592-8721, 2018, Volume 103, Issue 9, pp. 1502 - 1510
Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line treatment of chronic lymphocytic eukemia. Extended analysis of RESONATE-2... 
MIGRATION | CLL | MULTICENTER | CYCLOPHOSPHAMIDE | TYROSINE KINASE | RITUXIMAB | INITIAL THERAPY | OPEN-LABEL | MUTATIONS | HEMATOLOGY | FLUDARABINE | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 11/2013, Volume 119, Issue 21, pp. 3805 - 3811
BACKGROUNDThe combination of fludarabine, cyclophosphamide, and rituximab (FCR) has produced improved response rates and a prolonged survival in patients with... 
chronic lymphocytic leukemia | combination of fludarabine, cyclophosphamide, and rituximab | cytopenia | prognosis | DIAGNOSIS | PREDICTOR | and rituximab | CHEMOIMMUNOTHERAPY | GUIDELINES | combination of fludarabine | REGIMEN | ACUTE MYELOID-LEUKEMIA | MYELODYSPLASTIC SYNDROME | MAINTENANCE | ONCOLOGY | INITIAL THERAPY | cyclophosphamide | PROGRESSION-FREE | Myeloablative Agonists - therapeutic use | Cyclophosphamide - administration & dosage | Immunotherapy - methods | Myeloablative Agonists - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Young Adult | Aged, 80 and over | Clinical Trials, Phase II as Topic - statistics & numerical data | Adult | Female | Leukemia, Lymphocytic, Chronic, B-Cell - blood | Retrospective Studies | Leukemia, Lymphocytic, Chronic, B-Cell - immunology | Immune Tolerance - drug effects | Pancytopenia - chemically induced | Vidarabine - adverse effects | Pancytopenia - diagnosis | Rituximab | Treatment Outcome | Vidarabine - analogs & derivatives | Leukemia, Lymphocytic, Chronic, B-Cell - epidemiology | Immunotherapy - adverse effects | Leukemia, Lymphocytic, Chronic, B-Cell - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Pancytopenia - epidemiology | Adolescent | Aged | Vidarabine - administration & dosage | Pancytopenia - blood | Antibodies, Monoclonal, Murine-Derived - adverse effects | Chronic lymphocytic leukemia | Cyclophosphamide | Fludarabine | Dosage and administration | Research | Drug therapy, Combination | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 26, pp. 2531 - 2544
Journal Article
Current Pharmaceutical Design, ISSN 1381-6128, 2018, Volume 23, Issue 45, pp. 7003 - 7024
Journal Article
Journal of hematology and oncology, ISSN 1756-8722, 2018, Volume 11, Issue 1, pp. 110 - 10
Background: Thiotepa-busulfan-fludarabine (TBF) is a widely used conditioning regimen in single umbilical cord blood transplantation (SUCBT). More recently, it... 
Stem cell transplantation | Haploidentical stem cell transplantation | Acute myeloid leukemia | Conditioning regimens | Thiotepa-busulfan-fludarabine | Umbilical cord blood transplantation | HLA-MISMATCHED/HAPLOIDENTICAL BLOOD | BONE-MARROW-TRANSPLANTATION | UNRELATED DONORS | IDENTICAL-SIBLING TRANSPLANT | VERSUS-HOST-DISEASE | REDUCED-INTENSITY | ONCOLOGY | HIGH-RISK | ACUTE LYMPHOBLASTIC-LEUKEMIA | STEM-CELL TRANSPLANTATION | HEMATOLOGY | HEMATOLOGIC MALIGNANCIES | Thiotepa - therapeutic use | Busulfan - pharmacology | Busulfan - therapeutic use | Leukemia, Myeloid, Acute - pathology | Humans | Middle Aged | Male | Survival Rate | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Transplantation, Haploidentical - mortality | Transplantation Conditioning - mortality | Young Adult | Cord Blood Stem Cell Transplantation - methods | Vidarabine - pharmacology | Transplantation, Haploidentical - methods | Adult | Female | Aged | Retrospective Studies | Thiotepa - pharmacology | Cord Blood Stem Cell Transplantation - mortality | Transplantation Conditioning - methods | Leukemia, Myeloid, Acute - therapy | Fetal blood | Care and treatment | Leukemia | Physiological aspects | Transplantation | Research | Methods | Antigens | Graft-versus-host reaction | Statistical analysis | Transplants & implants | Disease | Hematology | Myeloid leukemia | Lymphocytes T | Multivariate analysis | Patients | Rejection | Grafts | Fludarabine | Cord blood | Lymphocytes | Stem cells | Bone marrow | Remission | Umbilical cord | Busulfan | Life Sciences
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 768 - 778
Journal Article
Oncotarget, ISSN 1949-2553, 09/2018, Volume 9, Issue 69, pp. 33124 - 33137
Fludarabine (flu) -containing regimens such as flu, cyclophosphamide and rituximab have been established as one of the standard first line therapy in... 
Ceramide | Chronic lymphocytic leukemia | Glucosylceramide | Fludarabine | Drug-resistance
Journal Article
Molecular Imaging and Biology, ISSN 1536-1632, 2/2014, Volume 16, Issue 1, pp. 118 - 126
Journal Article
Journal Article